(11 July 2024) Moderna’s combination vaccine against flu and COVID-19 showed a stronger immune response in a late-stage study compared to existing vaccines. The mRNA-1083 vaccine was tested on around 8,000 adults and showed mostly minor side effects. Moderna plans to present the data and seek FDA approval. Pfizer-BioNTech and Novavax are also studying similar vaccines.
Find out more here.
